lethithanhvy2001 3/14/2025 8:17:03 AM

Russia is on track to introduce its first cancer vaccine by early 2025, marking a significant milestone in medical innovation. This vaccine is developed by a Russian team in collaboration with major research institutions, including the Moscow State University and the Cancer Research Institute. It uses cutting-edge mRNA technology, which has already proven effective in COVID-19 vaccines, to target specific tumor cells and stimulate the body's immune response to fight cancer more effectively.

The vaccine is currently undergoing the final stages of clinical trials. These trials are designed to evaluate its safety and efficacy in treating certain types of cancers, particularly those related to lung and liver, which are among the most common globally. Preliminary results suggest that this vaccine could significantly improve survival rates and reduce recurrence risks for cancer patients, bringing hope to millions worldwide.

However, accessibility and affordability remain critical concerns. Experts highlight the potential challenge of high production costs, which may limit access to this life-saving innovation in lower-income regions. To address this, Russia is exploring partnerships with global health organizations and pharmaceutical companies to scale production and distribution. This effort aims to make the vaccine available to a broader population and integrate it into public health systems.

The introduction of this vaccine aligns with the growing global momentum in cancer prevention and treatment. Similar initiatives, such as trials conducted by BioNTech in the UK, underline the global effort to combat cancer with advanced technologies. If successful, Russia's vaccine could complement these efforts, marking a new era in the fight against one of the world's leading causes of death.

Question 18. Which of the following is NOT a feature of Russia's cancer vaccine?

A. It uses mRNA technology.

B. It is undergoing clinical trials.

C. It predicts specific cancer types.

D. It improves immune response to tumors.

Question 19. The word this in paragraph 3 refers to_______

A. the challenge of high production costs

B. the effort to make the vaccine available

C. the accessibility and affordability

D. the life-saving innovation

Question 20. The word preliminary in paragraph 2 could best be replaced by_______

        A. initial        B. final        C. conclusive        D. secondary

Question 21. The word accessibility in paragraph 3 is OPPOSITE in meaning to________

        A. uncertainty        B. unreliability        C. unpredictability        D. unavailability

Question 22. Which of the following best paraphrases the underlined sentence in paragraph 4?

A. The production of this vaccine demonstrates the potential of biotechnology in addressing global health challenges.

B. Efforts to create this vaccine emphasize the need for investment in medical research to tackle complex diseases.

C. The launch of this vaccine supports the increasing worldwide efforts in cancer prevention and treatment.

D. The development of this vaccine highlights the importance of collaborative research in advancing healthcare innovation.

Question 23. Which of the following is TRUE according to the passage?

A. Russia's cancer vaccine uses mRNA technology.

B. The vaccine has already completed all trials.

C. It will only be available for liver cancer.

D. Affordability is not a concern for its distribution.

Question 24. In which part of the text does the author mention the potential challenges of vaccine affordability?

        A. Paragraph 1        B. Paragraph 2        C. Paragraph 3        D. Paragraph 4

Question 25. In which part of the text does the author explain the broader global effort to fight cancer with vaccines?

        A. Paragraph 1        B. Paragraph 2        C. Paragraph 3        D. Paragraph 4

40. THPT Hậu Lộc 1 - Thanh Hóa (Tốt nghiệp THPT 2025 môn Tiếng Anh)